Life Sciences Archive » August, 2026

Life Sciences - August, 2026

258 articles

• Zimmer Wins Hip Implant Suit After Expert Testimony Tossed
• 9th Circ. Won't Rehear Eye Drop Antitrust Suit Despite Dissent
• How Did Litigants Fare In Judge Albright's 55 Patent Trials?
• Defamation Litigation Roundup: NYT, J&J, Azerbaijan
• SEC, FDA Enter Info-Sharing Pact To Bolster Enforcement
• Fed. Circ. Upholds Block On MSN Cancer Drug In Exelixis Win
• Judge Rejects AstraZeneca's Attack On Colo. 340B Law
• 9 More Drug Cos. Make Pricing Agreements With US
• Hospital Ex-Exec Pleads Not Guilty To $239M Testing Fraud
• Holland & Knight Adds Duo From McDermott Lobbying Arm
• Rising Star: Cooley's Bill Roegge
• Mead Johnson Prevails In 1st Infant Formula MDL Trial
• Ropes-Steered Lilly To Buy Goodwin-Led Merida For $2.9B
• Mead Johnson, Mom Clash On Formula Risks In Trial Closing
• AbbVie 'Concocted' Cancer Drug IP Claims, Biotech Firm Says
• Walmart Pays $50M To End DOJ's Suit Over Opioid Crisis
• Mylan, Lannett, Others Can't Split Up Humana Generics Trial
• AI-Bolstered Drug Co. Hits Ch. 11 With $105M Debt
• Fed. Circ. In July: Meeting The Enablement Requirement
• Parse Owes $4.9M In Cell Analysis Patent Case, Jury Finds
• Rising Star: Ropes & Gray's Ray Grant
• Medical Marijuana Industry Grapples With DEA's New Role
• Fla. Says PBMs Fixed Prices For Prescription Drugs
• 4 Arguments For Benefits Attys To Watch In September
• PBMs Hammer Opioid Judge In Last-Ditch Gambit At 6th Circ.
• Albertsons Loses Bid For Midtrial Win In Wash. Opioid Case
• Mead Johnson Nutrition Head Defends Formula In MDL Trial
• 5th Circ. Backs FDA, Pharma Cos. In GLP-1 Shortage Fight
• Guardant Suits Against Tempus AI Clear Dismissal Bids
• 23andMe Judge Slows Estimation Of Calif. Data Breach Claim
• Mich. Hospitals Defend CVS 340B Drug Savings Suit
• USPTO Sets Radiation Monitoring Patent Order As Informative
• Rising Star: Goodwin's Heath Ingram
• Taekwondo Makes Me A Better Lawyer
• 5th Circ. Upholds Drug Negotiations In Blow To Big Pharma
• Eton's Galzin TM And False Ad Suit Survives Dismissal Bid
• Humana Keeps Conspiracy Claims Against Mylan, Lannett
• 2nd Circ. Says Shield Law Covers Doctor In COVID Death Suit
• Idaho Abortion Ban Relief Narrowed To 1 Doctor
• Why AI Diligence Is Especially Key In IP Practice
• Rising Star: Sullivan & Cromwell's RuiHui 'Rachel' Yu
• Pot Distributor Again Files Counterclaims In Contract Dispute
• Albertsons Witness Says Co.'s Opioid Policies Beat Standards
• Ex-Taro Exec Slips Some Generics Price-Fixing Claims
• Health Exec Says CFO, Atty Knew Wage Claim Was Wrong
• AIDS Org 'Had Its Chance' To Sue Express Scripts, Judge Says
• Marijuana Rescheduling Critics Assail Government's Standard
• 23andMe, Calif. Spar Over Data Claims In Bankruptcy Court
• Lupin Beats Vertex's Patent Suit Over Cystic Fibrosis Drug
• Abbott Cuts $88.5M Deal To End Investors' Formula Recall Suit
• FDA Must Revisit Xifaxan Generic Exclusivity, DC Circ. Says
• Drugstores Beat Sun Pharma's $10M Racketeering Suit
• McKesson Snags Precision Medicine Group In $2.25B Deal
• Cooley Life Sciences Atty Joins Foley & Lardner In San Diego
• Rising Star: Williams & Connolly's Kathryn Kayali
• How 'Most Favored Nation' Regime Affects Biopharma Deals
• Judge Allows Hospital Groups To Fight AbbVie 340B Suit
• What To Know As Legal Duty To Consider AI Takes Shape
• 'So What?': Albertsons Judge Skeptical Of Wash. Opioid Suit
• DOJ Seeks To Beat UC Researchers' Challenge Of Grant Axings
• Biopharma Co. Brass Sued Over 'Channel Stuffing' Disclosures
• Judge Preserves, But Narrows, IP Verdict Against NuVasive
• Tribal Opioid Suits Against Sacklers Slated For $175M Exit
• Merck Loses HHS Suit Over Medicare Drug Price Program
• DOJ Backs Biotech Co. Against Red Cross At 1st Circ.
• Colo. Judge Certifies Class In Hospital Gender Care Suit
• DaVita Defeats Nurse Overtime Collective Bid
• Fed. Circ. Agrees To Speed Up Args In COVID Vax Patent Case
• 3 Firms Build Biotech Merger With $150M In Private Funding
• NC Dental Review Change Counters Tougher National Trend
• Judge Orders $245M In Guardant Damages In DNA Patent Suit
• NY Bill Would Boost Litigation Risk For Cosmetics Cos.
• Rising Star: Paul Weiss' Benjamin Goodchild
• Catching Up With Delaware's Chancery Court
• Cytek Hit With $56M Verdict For Infringing Cell-Sorting Patent
• Trump Seeks Justices' Review Of DEI Grant Termination Case
• Pharma Co. Loses Challenge To $3M Acne Drug Arb. Award
• Hogan Lovells Helps Advance Gene Therapy For Rare Disease
• How To Structure Protective Order AI Provisions In IP Disputes
• Astrid Investor Asks Chancery Court To Order Annual Meeting
• Bio-Techne Gives FTC More Time On $11.3B Merck Deal
• Appellate Vape Rulings May Expand State Regulation Powers
• 5 Lessons For VC Investors From Del. IPO Ruling
• Cook Medical Hit With Data Breach Class Suit
• Abbott Inks $670M Deal To End Some Preterm Formula Claims
• FTC Slams Amgen's Antitrust Shield Argument At 4th Circ.
• J&J Talc Unit Loses Libel Suit Over Flawed Cancer Study
• SEC Won't Lift Trading Suspension On Chinese Biotech Firm
• USPTO Tells Fed. Circ. 'Settled Expectations' Is Constitutional
• Canadian Bioscience Cos. Settle 'Fake' Fuel Trading Suit
• Latest Squires Order Grants 2 Patent Petitions, Denies None
• Fed. Circ. Rulings Emphasize Adjudicative Access And Review
• Amgen Reaches Deal To End Ex-Worker's Tobacco Fee Fight
• Sangamo Ch. 11 Auction Nets $238M In Offers
• Eagle Pharma $9.5M Investor Deal Gets Final OK
• Dentons Hires Longtime K&L Gates Healthcare Lawyer
• Being In A Band Made Me A Better Lawyer
• NYC's DNA Policies Led To Fabricated Evidence, Suit Says
• 5th Circ. Tells FDA To 'Rethink' Rule Behind E-Cig Rejection
• Abbott Deal Ends Appeal After $495M Baby Formula Trial Loss
• 1st Circ. Says Apellis Disclosures Weren't 'Half-Truths'
• Albertsons Says Wash. Failed To Prove Opioid Claims At Trial
• Double Patenting Ripe For Fresh Fed. Circ. Look Amid Debate
• Fed. Circ. Backs PTAB's Ax Of 10x Genomics Patent Claims
• FTC Asks Court To Keep Trans Health Suit In Texas
• Pro-Business Foundation Backs J&J's Stelara Antitrust Win
• HHS, USDA Must Withdraw Dietary Guidelines, DC Court Told
• Polsinelli Can't Rep Doctor In 'Bad Faith' IP Suits, Cos. Say
• Pa. Judge Rejects $360M Offset In Generics Antitrust Case
• 9th Circ. Says Initial Arbitration No Obstacle To EFAA
• Trump Taps White House Aide Overton To Lead FDA
• 10th Circ. Ruling Undermines False Ad 'Two Clicks' Rule
• How Drug Trial Prediction Markets Pose Insider Trading Risks
• Judge May Trim $88M Covidien Hernia Mesh Verdict
• Mich. Ruling Gives Consumer Protection Law Its Teeth Back
• Law School's Missed Lessons: Surviving A Long Trial
• At DC Circ., Pharma's Latest Pricing Loss Has Silver Linings
• DC Circ. Revives Part Of Fight Over Braille-Free Drug Label
• Mich. Fights Atty Fee Demand in Newborn Blood Spot Lawsuit
• DEA Blasts Marijuana Foes' Objections To Rescheduling
• AI Chatbot's Medical Claims Highlight Enforcement Risks
• BioMarin Buying Alesta Therapeutics For Up To $490M
• 11th Circ. Affirms Kickback Convictions For Pain Doc, Salesman
• Infant Formula MDL Judge Laments Ongoing 'Trial-By-Video'
• Medical Device Exec Cashed In On Bad Quarter, Feds Charge
• DLA Piper Taps Weil Partner As New York PE Co-Lead
• ​​​​​​​Catching Up With Delaware's Chancery Court
• Ga. High Court Sidesteps Key Question In Bio-Lab Fire Case
• Albertsons Judge Hears $44B Opioid Abatement Plan In Wash.
• COVID Test-Maker Inks $6.5M Investor Deal Over Sales Slump
• Moderna, Arbutus Clash On Gov't Venue For Vax IP Claims
• USPTO Backs Double Patent Policy Squires Wants Reviewed
• Home Sauna Kit Burned Consumer, Suit Says
• Medtech Group Faults Fed. Circ. Trade Secret Timing Rule
• Medtronic Rival Seeks Injunction After $382M Antitrust Win
• Latest Squires Patent Review Order Grants 1, Denies 3
• 7th Circ. Ruling May Reduce Litigation Risk For Text Marketers
• Biotech Asks 1st Circ. To Undo Red Cross Antitrust Immunity
• How Calif. Ruling Defines Drug Cos.' R&D Responsibilities
• AstraZeneca Joins States Aiming To Block Ill. 340B Drug Law
• 9th Circ. Says DOJ Subpoenas Can Support Trump Agenda
• 7th Circ. Won't Revive Elanco Investors' Securities Fraud Suit
• Idaho Abortion Ban Needs Health Exceptions, Judge Finds
• Midyear Trends, Takeaways As Securities Class Actions Surge
• First Baby Formula MDL Trial To Kick Off In Chicago
• Albertsons Didn't Flag Suspicious Opioid Orders, Judge Hears
• Bristol-Myers Can't Duck UMB Suit Targeting Drug Approvals
• 9th Circ. Revives $140M Robo-Surgery Antitrust Case
• CIBC Deal Ends Hedge Fund's Pharma Stock Spoofing Suit
• J&J Says No To Reviving Stelara Case
• 4th Circ. Won't Undo Block Of Gilead-Branded Drug Imports
• Judge Tosses Suit Over Pharmacy Match Program, For Now
• 3rd Circ. Upholds Dismissal Of Lipitor Pay-To-Delay Case
• P&G, Arm & Hammer Sued Over Unscented Deodorant Claims
• Lilly Claims 6 Vendors Illegally Sold Obesity Drug Candidate
• Employers Expecting Bump In Health Plan Costs, Survey Says
• Glenmark Will Pay $15.3M To End Humana's Price-Fixing Claims
• NC Biz Court Bulletin: Judges Retire, HCA Suit Heads To Trial
• Brighthouse Strikes $9.25M Deal In Life Policy Rate Suit
• Going To Hardcore Shows Makes Me A Better Lawyer
• Full 5th Circ. Rejects Planned Parenthood's Immunity Appeal
• Albertsons Judge Hears Testimony On Rx Opioid, Abuse Link
• Compliance Officer's Partner Traded On Deal Info, SEC Says
• Del. Judge Slashes Fee Bid For 'Underwhelming' Settlement
• 'Core' Generics Leader Must Face Most AG Price-Fix Claims
• Hogan Lovells Adds Senior FDA Official In DC
• 9th Circ. Says Aetna Must Face Benefit Misrepresentation Suit
• CMS Ends Medicaid Funds For Youth Transgender Care
• Abbott, Mead Must Face Baby Formula Retrial, Mo. Panel Says
• USPTO Simplifies Entry To Patent Bar For Biomedical Grads
• Full Fed. Circ. Declines To Revisit Design Patent Test
• How Home Infusion Providers Can Adapt To Enrollment Pause
• Fed. Circ. Revives Man's Vax Injury Case, Citing Mail Delay
• Judge Probes 7th Circ. Fallout Of Ending Gender Care Fight
• USPTO Practitioner Roster Reflects A More Veteran Workforce
• Neogen Beats Investor Suit Over 3M Integration Claims
• DOJ Drops 3rd Circ. Bid For Pa. Hospital Trans Patient Info
• Pharma Co. To Pay $46M Over Transplant Drug Kickbacks
• Drugmakers Lose 2nd Bid To Appeal Ex-Prosecutor DQ Rebuff
• Trump Revives Push To Reduce Kids' Vaccine Schedule
• AbbVie, Novartis Seek To Block Ill. 340B Drug Discount Law
• Opioid Victims Say Firm Kept Too Much Of Purdue Payouts
• Welch Allyn, IRhythm Reach Deal To End Patent Dispute
• Lack Of Fiduciary Duty Frees Chemours From NC PFAS Suit
• Alto Neuroscience Escapes Investor Drug Trial Suit, For Now
• Fed. Circ. Reverses PTAB On Prior Art Issue Over Dental IP
• Judge Blocks DOD Military Label For Chinese Biotech Co.
• Catching Up With Delaware's Chancery Court
• Jazz Pharma Buying Actio In Up To $1.32B Epilepsy Push
• EU Sets Antidumping Duties On Plastic Compound Imports
• 3rd Circ. Says Pharma Co. Suit Against Merck Belongs In India
• VA To Test Psilocybin For Veterans With Severe Depression
• Glenmark's $29.6M Generics Price-Fixing Deal Gets 1st OK
• J&J Fax Sent To Pharmacy An Unwanted Ad, 3rd Circ. Says
• How 'Markedly Different' Test Shapes Patent Eligibility Debate
• 2nd Circ. Tylenol Ruling Misapplies Daubert Gatekeeping
• New Squires Order Institutes 4 Patent Reviews, Denies 6
• KKR Buying Medicover's India Business In $1.4B Deal
• 5 Antitrust Lessons On Bundled Discounts After Medtronic
• Nat'l Science Org. To Review Judiciary's Nixed Climate Chapter
• Eli Lilly Launches Attacks On Tirzepatide Generics
• Cooley Leads 2 Biotech Firms Pricing IPOs Totaling $496M
• Taxation With Representation: Slaughter And May, Covington
• Mead Preemption Bid Fails Before 1st Baby Formula MDL Trial
• USPTO Leaders Reinstate Double Patenting Ax In Sanofi Case
• Mark Zuckerberg's Foundation Can Arbitrate Gender Bias Suit
• SEC Nets Win In Suit Over Ex-CEO's Alleged Revenue Scheme
• SpineFrontier CFO Sentenced To 4 Months In Kickback Case
• GOP Sens. Vote To Hold Fauci In Contempt, AGs Open Probe
• Judge Sets Feb. Trial In States' Generics Price-Fixing Suit
• After Monsanto, Defense Bar Must Build Case Against Lohr
• A New Era Of Scrutiny For China-Linked Pharma Deals
• Goodwin, Covington Lead Braveheart Bio's $383M IPO
• Tarsus Bets Up To $800M On Alkeus In Retina Therapy Push
• Eli Lilly, Novo Nordisk Antitrust Suit Tossed By Texas Judge
• Being A Sommelier Makes Me A Better Lawyer
• Judge OKs $35M Teva Deal In Delayed Generic Inhalers Suit
• 2025 Patent Litigation: A Year In Review
• Product Liability Cases To Watch: Midyear Report
• Unread Arbitration Emails Are Unenforceable, 9th Circ. Rules
• Drug Cos. Can't Trim Humana's Price-Fix Claims In Bellwether
• Stewart Says Patent System 'Crisis' Fueled USPTO Changes
• Kansas Judge Permanently Blocks Abortion Care Restrictions
• Panel Rejects BMS Investor's Bid To 'Camouflage A Wolf'
• Chancery Sets Hybrid Interest Formula In Alexion Merger Fight
• Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict
• Aetna, Others Hit Pharma Cos. With Xifaxan Pay-To-Delay Suit
• Mich. Parents Seek $375K In Newborn Blood Spot Case
• These Firms Are Picking Up The Most PTAB Work
• Fenwick-Led Attovia Therapeutics Prices Upsized $289M IPO
• Calif. Drug Ruling Affirms Defect-Centric Liability Framework
• Glenmark Pharma Hit With Safety Suit After Carvedilol Recalls
• Revive Rx Can't End Eli Lilly's Suit Over Tirzepatide Drugs
• PTAB Filings Crashed After Squires And Stewart's Shake-Ups
• New Patent Suits Surge As PTAB Challenges Get Tougher
• These Firms Are Landing The Most Patent Litigation Work
• 3rd Circ. Won't Give Ex-Olympus Exec Another Go At FCA Suit
• Kirkland, Jones Day Guide P&G's $3.8B Buy Of Thorne
• Biotech Founder Claims He Was Excluded From GSK Deal
• Saxena White Seeks To Lead GeneDX AI Acquisition Row
• Navigating Court Divergence On Method Claims And Venue
• Fed. Circ. Won't Reopen Lidocaine Patch Patent Suit
• Workers Say Trump's Gold Card Lets Rich Jump Visa Line
• Bellwether Jury Awards $88M In Covidien Hernia Mesh Trial
• Albertsons Says Wash. Slow To Warn Of Bad Drug Prescribers
• Calif. Justices Back Gilead Over Nondefective Drug Liability
• 7th Circ. Backs OB-GYN's 10-Year Healthcare Fraud Sentence
• Novo False-Ad Claims Against Telehealth Co. Fail, For Now
• 4 Firms Steer Curium's $8B Lantheus Take-Private Deal
• Sandoz Settles States' Generics Price-Fixing Cases For $450M
• NJ Supreme Court Ruling Exposes D&O Gaps For PE Boards
• Baker Botts Hires Litigators In DC And London
• Fed. Circ. In June: When Courts Can't Correct Patent Errors
• Pfizer COVID Vaccine Suit Needs 3-Judge Court, Panel Finds
• KKR Buying Integer For $5.7B In Kirkland, Davis Polk-Led Deal
• Bath Product Maker Vi-Jon Hits Ch. 11 With $25M Talc Deal
• Former Gates Foundation Deputy GC Joins Arnold & Porter
• Law360 Names 2026's Top Attorneys Under 40